A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621 a Novel Biologic Targeting CD47 in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Brief description of study
If you have been diagnosed with Lymphoma, Leukemia, Myelodysplastic syndrome, Myeloproliferative neoplasms, or Multiple myeloma, that has returned or worsened since your previous treatment, you may be qualified for this Phase Ia/Ib study evaluating the investigational drug TTI-621. The main goal of this study is to test the safety of TTI-621 when it is given in combination with other anti-cancer drugs, rituximab or nivolumab.
Clinical Study Identifier: s17-01012
ClinicalTrials.gov Identifier: NCT02663518
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
